These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
502 related articles for article (PubMed ID: 23473350)
1. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. McEvoy JP; Citrome L; Hernandez D; Cucchiaro J; Hsu J; Pikalov A; Loebel A J Clin Psychiatry; 2013 Feb; 74(2):170-9. PubMed ID: 23473350 [TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia. Awad G; Hassan M; Loebel A; Hsu J; Pikalov A; Rajagopalan K BMC Psychiatry; 2014 Feb; 14():53. PubMed ID: 24559217 [TBL] [Abstract][Full Text] [Related]
3. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Citrome L Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. Citrome L; Weiden PJ; McEvoy JP; Correll CU; Cucchiaro J; Hsu J; Loebel A CNS Spectr; 2014 Aug; 19(4):330-9. PubMed ID: 24330868 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. Stahl SM; Cucchiaro J; Simonelli D; Hsu J; Pikalov A; Loebel A J Clin Psychiatry; 2013 May; 74(5):507-15. PubMed ID: 23541189 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311 [TBL] [Abstract][Full Text] [Related]
7. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Citrome L Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135 [TBL] [Abstract][Full Text] [Related]
8. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992 [TBL] [Abstract][Full Text] [Related]
9. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Potkin SG; Ogasa M; Cucchiaro J; Loebel A Schizophr Res; 2011 Nov; 132(2-3):101-7. PubMed ID: 21889878 [TBL] [Abstract][Full Text] [Related]
10. Lurasidone in schizophrenia: new information about dosage and place in therapy. Citrome L Adv Ther; 2012 Oct; 29(10):815-25. PubMed ID: 23001538 [TBL] [Abstract][Full Text] [Related]
11. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. Nasrallah HA; Silva R; Phillips D; Cucchiaro J; Hsu J; Xu J; Loebel A J Psychiatr Res; 2013 May; 47(5):670-7. PubMed ID: 23421963 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Loebel A; Cucchiaro J; Xu J; Sarma K; Pikalov A; Kane JM Schizophr Res; 2013 Jun; 147(1):95-102. PubMed ID: 23583011 [TBL] [Abstract][Full Text] [Related]
13. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. Loebel AD; Siu CO; Cucchiaro JB; Pikalov AA; Harvey PD CNS Spectr; 2014 Apr; 19(2):197-205. PubMed ID: 24330860 [TBL] [Abstract][Full Text] [Related]
14. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Citrome L Postgrad Med; 2011 Mar; 123(2):153-62. PubMed ID: 21474903 [TBL] [Abstract][Full Text] [Related]
15. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. Potkin SG; Keator DB; Kesler-West ML; Nguyen DD; van Erp TG; Mukherjee J; Shah N; Preda A CNS Spectr; 2014 Apr; 19(2):176-81. PubMed ID: 24073841 [TBL] [Abstract][Full Text] [Related]
16. Lurasidone: a new treatment option for schizophrenia. Owen RT Drugs Today (Barc); 2011 Nov; 47(11):807-16. PubMed ID: 22146224 [TBL] [Abstract][Full Text] [Related]
17. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950 [TBL] [Abstract][Full Text] [Related]
18. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. Karayal ON; Glue P; Bachinsky M; Stewart M; Chappell P; Kolluri S; Cavus I J Psychiatr Pract; 2011 Mar; 17(2):100-9. PubMed ID: 21430488 [TBL] [Abstract][Full Text] [Related]
19. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Citrome L Clin Schizophr Relat Psychoses; 2011 Jan; 4(4):251-7. PubMed ID: 21177242 [TBL] [Abstract][Full Text] [Related]
20. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]